On the last trading session of the week, we may see the market opening on a flat note and there is likelihood that it may continue to trade in a range before the index kicks off the next leg of the rally. Stocks in news: Maruti Suzuki India, BEML, Gati, TCS, Persistent Systems, Tree House Education and Accessories, NBCC, Astrazeneca Pharma, Lemon Tree Hotels, MCX, ION Exchange and Cosmo Films.

A quiet opening is expected for the Indian markets and we may see the markets trading in a range with stock-specific movement. The muted trend in the SGX Nifty suggests that Nifty could open unchanged at 11,421.  

The stocks that are likely to witness significant movement on the bourses on August 17 are Cosmo Films, V-Mart, Tata Consultancy Services, Niraj Ispat Ind. and Infibeam.

On August 14, 2018, Andhra Pradesh Capital Region Development Authority (“APCRDA”) successfully raised Rs. 2000 crores by issuing bonds on private placement basis using BSE BOND platform.

The share price of Patel Engineering Company jumped about 12 per cent on Thursday after the company reported profit of Rs. 36.2 crore for the quarter ended June 2018.

This film has been specially designed to offer superior inter-layer bond strength for making multi-layer laminate structures, which in turn enhances barrier properties, said the company in a filing to the bourses.

Suven Life Sciences reported its results for the quarter ended June 30, 2018. The company’s standalone revenue for the quarter came in at Rs. 191.66 crore, registering 35.9 per cent yoy increase. This was mainly driven by a jump in revenue from the manufacturing segment by 35.2 per cent yoy.

Lira, the currency of Turkey, has fallen by 40 per cent the year till date with a fear of contagion being spread to other emerging countries including India.

 The company has an order book of more than Rs. 80,000 crore in hand. This leads to book/bill ratio of 13x which is highest amongst infrastructure companies.

The stock of pharma major Dr. Reddy's Laboratories was buzzing on Thursday as market expected the company to receive US drug regulator's approval for blockbuster cancer drug imatinib mesylate.